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Background: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy without an available effective
systemic chemotherapy. Insulin growth factor 2 (IGF-2) overexpression leading to the activation of the IGF-1 receptor (IGF-1R)/
mammalian target of rapamycin (mTOR) pathway is well described in ACC. Cixutumumab, a fully human IgG1 monoclonal
antibody directed at IGF-1R was combined with temsirolimus on the basis of preclinical data.
Methods: Patients received cixutumumab, 3–6mgkg 1 intravenously (IV) weekly, and temsirolimus, 25–37.5mg IV weekly (4-week
cycles), with restaging after 8 weeks.
Results: Twenty-six patients were enrolled (13 (50%) men); median age, 47 years; median number of prior therapies, 4. Five
patients previously received an IGF-1R inhibitor and one, temsirolimus. The most frequent toxicities, at least possibly drug related,
were grade 1–2 thrombocytopenia (38%), mucositis (58%), hypercholesterolaemia (31%), hypertriglyceridemia (35%), and
hyperglycaemia (31%). In all, 11 of 26 patients (42%) achieved stable disease (SD)46 months (duration range¼ 6–21 months) with
3 of the 11 having received a prior IGF-1R inhibitor.
Conclusion: Cixutumumab combined with temsirolimus was well tolerated and 440% of patients achieved prolonged SD.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy
with an estimated annual prevalence of 0.5 to two cases per million
population, and with many cases presenting as locally advanced or
metastatic disease (Kebebew et al, 2006; Golden et al, 2009).
Complete surgical resection, when feasible, is the optimal thera-
peutic strategy for improving survival (Lee et al, 1995; Grubbs et al,
2010). Despite best treatment efforts, patients with stage IV disease
have a disease-specific survival at 5 years of only 13% (Fassnacht
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et al, 2009). The limited efficacy of standard-of-care therapy has
led to the search for new treatment options.
Insulin growth factor 2 (IGF-2) is the single most upregulated
transcript in as many as 80–90% of ACC cases. It is known to
induce the activation of IGF-1 receptor (IGF-1R) and the insulin
receptor (IR) (Fottner et al, 2004; Almeida et al, 2008; Barlaskar
et al, 2009). During the dose escalation part of our phase I study
with the IGF-1R inhibitor cixutumumab and the mammalian
target of rapamycin (mTOR) inhibitor temsirolimus, antitumor
activity was observed in metastatic ACC (Naing et al, 2011).
Upstream tyrosine kinases such as IGF-1R regulate the PI3K/AKT/
mTOR pathway (Liu et al, 2009). Furthermore, in vitro, in vivo,
and tumour biopsy studies demonstrate that mTOR inhibitors
activate a feedback loop, which results in upregulated AKT
phosphorylation in tumour tissue via an IGF-1R-dependent
mechanism (Hay and Sonenberg, 2004; Shi et al, 2005; O’Reilly
et al, 2006; Wan et al, 2007). Pharmacologic inhibition of mTOR
signalling by everolimus reduces ACC tumour cell lines growth
in vitro and in vivo (Doghman et al, 2010).
The double targeting of the IGF1R-AKT-mTOR pathways by
utilising two drugs that act at two different points in the pathways
is a logical rationale. Hence, treatment with a combination of an
IGF-1R inhibitor and an mTOR inhibitor would be a rational way
to target ACC and circumvent resistance. Here, we report a cohort
of 26 patients with ACC who were treated in an expansion cohort
of our phase I study of the IGF-1R inhibitor cixutumumab and the
mTOR inhibitor temsirolimus (Naing et al, 2011).
MATERIALS AND METHODS
Study design. The patients reported herein were an expansion of a
phase I, dose-expansion study that was conducted at The
University of Texas MD Anderson Cancer Center and the Barbara
Ann Karmanos Cancer Institute at Wayne State University (Naing
et al, 2011). Twenty-six patients with ACC received cixutumumab,
6mg kg 1 intravenously (IV) weekly, and temsirolimus, 25mg
(N¼ 24) to 37.5mg (N¼ 2) IV weekly. Treatment cycles were
4 weeks with restaging after B8 weeks. This study was performed
according to the principles embodied in the Declaration of
Helsinki and after approval by the institutional review boards of
both study centres. Informed consent was obtained from all
patients enrolled on the study.
Toxicity. The severity of toxicity was assessed according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE), version 3.0 initially and later
changed to version 4.0 (per CTEP recommendation). Temperature,
blood pressure, and pulse were measured before each infusion.
Haematology, blood chemistry and urinalysis, and physical
examinations were also monitored every week.
Evaluation of efficacy. Treatment efficacy was evaluated by
computed tomography (CT) or magnetic resonance imaging
(MRI) per Response Evaluation Criteria in Solid Tumours
(RECIST) (Therasse et al, 2000) before treatment and approxi-
mately every 8 weeks thereafter. Briefly, a complete response (CR)
was disappearance of all lesions, partial response (PR) was aX30%
reduction in the sum of the longest diameters of the lesions, stable
disease (SD) was denoted in patients whose sum of longest lesion
diameters were not decreased 430% and not increased 420%,
and progressive disease (PD) was a X20% increase in the sum of
the longest diameters of the lesions. A response had to last for at
least 4 weeks to be considered as a PR or CR. Patients with SD
lasting 6 months or longer were considered to have durable SD.
RESULTS
Patient characteristics. A total of 26 patients (13 men) with
advanced metastatic and/or refractory ACC were enrolled on the
study. Median age of participants was 47 years (range, 20–
74 years). All pathologic diagnoses were confirmed at MD
Anderson or Wayne State University. The number of tumour
organs involved at study entry for all 26 patients is 1–4, and the
most common site is lung. Ten out of twenty-six patients were
documented to have secreting ACC. Three patients received prior
IGF-1R inhibitor treatment, one patient was on a randomised trial
and received either placebo or IGF-1R inhibitor treatment, and one
patient had been previously treated with temsirolimus. Most
patients had been heavily pretreated, with the median number of
prior therapies being 4 (range 0–8).
Toxicities. The current study represents an expansion of a
previous phase I dose escalation study (Naing et al, 2011).
The 26 patients reported in this study with ACC had the
following toxicities, that were at least possibly drug-related
at both dose levels, but most instances of them were grade 1 or
2 (Table 1): mucositis (n¼ 15), thrombocytopenia (n¼ 10),
hypertriglyceridemia (n¼ 9), hypercholesterolaemia (n¼ 8), and
hyperglycaemia (n¼ 7). Hyperglycaemia was managed in colla-
boration with an endocrinologist. Two patients who were diabetic
at baseline were controlled by insulin and sitagliptin or by glipizide.
Two of the rest of the twenty-four study patients developed
diabetes mellitus on study, which was well controlled with the use
of metformin alone (n¼ 1), and insulin together with metformin
and glipizide (n¼ 1).
We have previously reported toxicities in the heterogeneous
tumour type population as well as the Ewing’s sarcoma family
tumours treated with this drug combination (Naing et al, 2011,
2012). Compared with the patients with heterogeneous
tumour types and Ewing’s sarcoma family tumours, there
were no peculiar toxicities that were unique to ACC patients. We
Table 1. Common treatment-related toxicities
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Mucositis (includes gingivitis) 12 3
Hypercholesterolaemia 7 1 1
Hypertriglyceridemia 7 2 1 1
Thrombocytopenia 6 4 2
Hyperglycaemia 5 2 3
Fatigue 5 1
Rash 5 2
Pruritis 3
Nail changes 3
Myalgia (includes bone pain) 3
Floaters/light flashes 3
Dysgeusia 2
Anorexia 2 2
Nausea 2 1
Elevated AST/ALT 2 7
Elevated creatinine 2 2
Xerostomia 1
Allergic Rxn/hypersensitivity 4
Neutropenia 1 3
Abbreviations: AST¼ aspartate aminotransferase; ALT¼ alanine aminotransferase.
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did not observe a difference of toxicity for patients who had
secreting ACC.
Antitumor activity. Tumour response was assessed by RECIST
criteria (Therasse et al, 2000). The best responses for the 26 study
patients are shown in the waterfall plot in Figure 1. In all, 11 of
26 patients (42%) had SD X6 months. Three out of the eleven
responders were documented to have secreting ACC. Two patients
whose tumours remained stable for at least 8 months had prior
IGF-1R inhibitor treatment.
DISCUSSION
Many patients with ACC present with locally advanced or
metastatic disease (Kebebew et al, 2006; Golden et al, 2009).
Eighty percent of patients have disease recurrence within 2 years
after curative surgery, and common sites of metastasis are liver,
lung, and adjacent organs. In patients with recurrent ACC, disease-
free survival after curative surgery is 12.1 months (Luton et al,
1990; Wooten and King, 1993). Unfortunately, the available
systemic therapeutic options do not consistently result in effective
cytoreduction. The limited efficacy of available systemic che-
motherapy led to a search for new treatment options based on the
underlying molecular mechanisms involved in ACC.
Insulin growth factor 2 (IGF-2) is upregulated in ACC; and
IGF-2 signalling is mediated through its interaction with the IGF-
1R, which leads to downstream activation of mTOR (Pavelic et al,
2002; Demeure et al, 2011). Cixutumumab is a fully human
monoclonal antibody that inhibits IGF-1R. Preclinical in vitro and
animal studies showed reduced ACC cell proliferation induced by
cixutumumab that was augmented in combination with the
antineoplastic agent mitotane (Barlaskar et al, 2009). During our
dose escalation study, 4 out of 10 ACC patients had SD over
8 months (Naing et al, 2011). The dose expansion phase was then
done in an additional 16 patients. As reported here, 11 out of a
total of 26 patients (42%) had durable (X6 months) SD. There
were, however, no PR or CRs in the study patients. In the
11 patients who had SD over 6 months, the median time to
progression (TTP) on combination of temsirolimus and cixutu-
mumab was 9 months compared with 4 months of median TTP on
their previous treatment regimen.
Recent preclinical study showed that sirolimus inhibits cortisol
secretion in ACC (De Martino et al, 2012). In this study, 10 out of
26 patients were documented to have secreting ACC, and
hormonal levels were not analysed throughout the study. One
responder and one non-responder were managed by board-
certified endocrinologists for hormonal-related symptoms; there-
fore, it is unclear whether this combination of temsirolimus and
cixutumumab affected the hormone levels or improved hormonal-
related symptoms in these patients with ACC.
Temsirolimus is metabolised by the microsomal liver enzyme
cytochrome P450 (CYP3A4/5). Drugs interfering with these
enzymes were suspended 4 weeks before starting the protocol
treatment (Naing et al, 2011). Mitotane is the most commonly used
drug for the treatment of ACC and can induce this enzyme, and it
may cause sub-therapeutic levels of temsirolimus.
Most of our patients had been heavily pretreated, with the
median number of prior regimens being 4. Ten out of twenty-six
patients received mitotane as their most recent treatment before
enrolling in our study. Ideally, mitotane plasma levels should be
o5 mgml 1 at baseline; however, in our study, the mitotane levels
in each patient were not recorded. Four patients had received prior
treatment with an IGF-1R inhibitor (n¼ 3) or mTOR inhibitor
(n¼ 1) and one patient had previously been on a randomised,
blinded trial and received either placebo or an IGF-1R inhibitor.
Prior use of and progression on a single agent IGF-1R inhibitor did
not preclude a prolonged SD response to the combination of an
IGF-1R inhibitor and an mTOR inhibitor. Two of three patients
with prior IGF-1R inhibitor treatment achieved durable (X6 months)
SD. One patient was a 34-year-old woman who was treated with a
single-agent IGF-1R inhibitor for nearly 10 months. Upon
progression, she was enrolled on our trial and remained stable
for 10 months. The second patient’s tumour remained stable on
our combination treatment trial of temsirolimus and cixutumumab
for 9 months. There was also a third patient who was a
62-year-old woman who had previously been treated with either
placebo vs IGF-1R inhibitor for 3 months before being enrolled on
our study. The patient’s tumour remained stable for 8 months.
Overall, this regimen was well tolerated. Side effects were
manageable and patients continued to maintain their performance
status until their disease progressed. Endocrine complications such
as hyperglycaemia and hyperlipidemia were observed. This was not
unexpected since a concern for this class of drugs, especially the
IGF-1R inhibitors, is that they induce hyperglycaemia (Haluska
et al, 2010). As a result, many studies restrict eligibility so that
patients with elevated blood glucose cannot enrol. This study was
not restricted in this way. We found that hyperglycaemia was
managed with oral hypoglycaemia agents, with or without insulin,
and patients (N¼ 2) who were diabetic at baseline did not worsen.
Only two patients who were not diabetic at baseline became
diabetic on study, and they were managed with metformin alone
(n¼ 1) or oral hypoglycaemia agents and insulin (n¼ 1). The
second patient on oral hypoglycaemia agents and insulin remained
stable for 12 months. It is not clear if his diabetes was reversible
after discontinuation of study drugs, as he returned home to a
foreign country after 12 months, and was lost to follow-up. These
results, along with those from our previous study demonstrated
that patients who develop metabolic side effects such as
hyperglycaemia or more significant myelosuppression during the
study may have superior responses. Furthermore, those who
develop worsening hyperglycaemia should be treated for high
blood sugar rather than removed from the trial (Naing et al, 2012).
Treatment of ACC remains challenging and the efficacy of
current therapies such as mitotane and etoposide has been dismal.
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Figure 1. 3D RECIST Waterfall plot. Best response by RECIST in 26
treated patients with ACC. Dose level 3 (N¼24) was cixutumumab,
6mgkg 1 IV weekly, and temsirolimus, 25mg IV weekly. Dose level 4
(N¼ 2) was cixutumumab, 6mg kg 1 IV weekly, and temsirolimus,
37.5mg IV weekly. Patients with early clinical progression or with new
lesions or clinical progression or who came off early for any reason are
indicated on the graph as a 21% increase (*).
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First-line treatment on a combination of etoposide, doxorubicin,
and cisplatin (EDP) with mitotane produced a better rate of
response and progression-free survival compared with streptomy-
cin plus mitotane, however, overall survival remained disappoint-
ing at o15 months (Fassnacht et al, 2012). Various targets and
agents have been explored in ACC (Almeida et al, 2008; Demeure
et al, 2011). The epithelial growth factor receptor (EGFR) tyrosine
kinase inhibitor gefitinib did not show efficacy as a single agent in
ACC (Samnotra et al, 2007). Similarly, sunitinib exhibited modest
activity as a single agent in mitotane-exposed ACC patients (Kroiss
et al, 2012). Other pathways such as those involving fibroblast
growth factor receptor (FGFR) and Wnt-b-catenin signalling
cascades and loss of p53 function have been implicated in ACC
tumorigenesis. The development of strategies targeting these
pathways may also be worthwhile (Demeure et al, 2011; Simon
and Hammer, 2012). This trial shows promise in the management
of refractory ACC. However, without conducting a randomised
phase II/III trial, it is unclear whether this treatment regimen
would be more effective than second-line or third-line standard
therapy.
The combination of cixutumumab and temsirolimus
demonstrates modest activity in refractory ACC as well is in other
types of cancer such as Ewing’s sarcoma and desmoplastic
small-round-cell tumours (DSRCT) (Naing et al, 2012). Our
patients with ACC were heavily pretreated and future studies in
larger numbers of patients with ACC are needed to better evaluate
the benefit of this treatment, perhaps earlier in the course of their
disease.
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PRE´CIS
The combination of cixutumumab and temsirolimus was well
tolerated in patients with rare and aggressive ACC. More than 40%
of ACC patients achieved prolonged SD using this combination.
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